Is Vertex CEO Jeff Leiden paid too much?; Pulmotect gets $3M grant to fuel clinical study;

@FierceBiotech: UPDATED: Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep. Story | Follow @FierceBiotech

@JohnCFierce: CAR-T powerhouse Juno allies with gene-editing upstart Editas in $737M deal. Article | Follow @JohnCFierce

> Corporate governance adviser Institutional Shareholder Services (ISS) believes Vertex ($VRTX) chief Jeff Leiden is overpaid. ISS is urging shareholders to censure the executive pay in a non-binding vote of disapproval June 4, reports Bloomberg. Leiden's pay packet last year was worth $45.8 million. Story

> Houston-based Pulmotect has won a $3 million grant from the NIH to help advance its immunotherapy in the clinic. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: SI-Bone raises $21M, brings on new CFO to grow iFuse implant sales. Article | Follow @FierceMedDev

@VarunSaxena2: Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Cancer Genetics strikes genomics deal with Japanese regenerative medicine company. More from FierceDiagnostics | Follow @EmilyWFierce

> CareFusion's Avea ventilator recalled as potentially deadly, FDA says it may cease functioning. Article

> Scientists push back against cancer hereditary genetic tests in NEJM paper. More

> Varian, Flatiron Health to collaborate on oncology electronic health records. Report

Pharma News

@FiercePharma: Regeneus gets green light to move personalized cancer vaccine into PhI. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik. FiercePharmaMarketing article | Follow @CarlyHFierce

> Express Scripts pushes pay-for-performance to cut cancer drug prices. Report

> Top Medicare prescribers get top payments from drugmakers: Modern Healthcare. More

> Vertex CEO's $45.8M paycheck spurs call for revolt. Article

Pharma Marketing News

> My bathtub or yours? How a panned Cialis ad became promotional gold. More

> Revving up for price war with Amgen, Sanofi plots low-cost starter dose of PCSK9 med. Story

> Do doc payments push prescriptions? Study of Medicare scripts suggests it's so. Item

> AZ, Daiichi sign up Olympian Joyner-Kersee, hoping OIC patients will make tracks to Movantik. Article

> Can AZ salvage brodalumab against next-gen psoriasis field? More

Biotech Research News

> Dana-Farber researchers tout a new class of cancer-fighting 'degronimids.' More

> Pitt team unveils two new classes of RNAs for cancer drug R&D. Report

> The White House draws the line against CRISPR/Cas9-designed embryos. Story

> Thunder god vine compound may have potent anti-obesity characteristics. More

> Winship research team flags potential of a new lung cancer therapy. Article

Diagnostics News

> MBio receives $6.3M in support of its portable, optical diagnostic. Story

> Cancer Genetics strikes genomics deal with Japanese regenerative medicine company. Item

> Quest Diagnostics shares hit record high amid takeover rumors. Report

> Roche gets FDA green light for quick C. difficile test. Article

> Sequenom stares down suit from Indian genomics firm. More